临床试验/NCT00185302

NCT00185302已完成2 期

Phase II Study of MS-275, a Histone Deacetylase Inhibitor, Comparing 2 Dosage Schedules in Patients With Metastatic Melanoma

Bayer0 个研究点目标入组 28 人开始时间: 2004年12月最近更新: 2015年12月14日

适应症

干预措施

试验速览

阶段: 2 期
状态: 已完成
发起方: Bayer
入组人数: 28
主要终点: Overall tumor response rate (the proportion of subjects with the best tumor response of PR or CR within the first 6 cycles of treatment)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

Primary objective: To evaluate the efficacy of two different dosing schedules of MS-275 in subjects with metastatic melanoma Secondary objectives: To evaluate the safety and to assess the pharmacokinetic profile of MS-275 in subjects with metastatic melanoma

详细描述

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Adult subjects with Stage III or IV non-resectable nonuveal (cutaneous or mucosal) metastatic melanoma who had received at least one but no more than two previous systemic therapies (immunotherapy and/or chemotherapy) for metastatic disease and who had not responded to or who had progressed after their most recent therapy were eligible for enrollment
•Presence of at least one lesion fulfilling the minimum Response Evaluation Criteria in Solid Tumors (RECIST) size requirements for a target lesion - Use of highly effective birth control methods in females of child-bearing potential
•Able to undergo either contrast enhanced computed tomography (CT) scan or contrast enhanced magnetic resonance imaging (MRI) scan for tumor assessment
•Life expectancy greater than 3 months
•Adequate organ and bone marrow functions as defined below: absolute neutrophil count ≥ 1500 /µL, platelets ≥ 100,000 /µL, creatinine ≤ 1.5 × upper limit of normal (ULN) or measured creatinine clearance of ≥ 60 mL/min x 1.73 m2 body surface area, total bilirubin ≤ 1.5 times ULN, aspartate aminotransferase or serum glutamic oxalacetic transaminase/alanine aminotransferase or serum glutamic pyruvic transaminase∗ ≤ 2.5 times ULN
•Negative serum pregnancy test within 2 weeks prior to receiving the first dose of study drug in female subjects of childbearing potential. Agreement to use a highly effective method of birth control throughout the study period and 3 months thereafter for sexually active males and females of childbearing potentia

排除标准

•Active malignancy in the last five years
•Pregnancy, breast feeding
•HIV infection
•Brain metastasis
•Concomitant use of corticosteroids or valproic acid
•Uncontrolled intercurrent illness
•Diagnosis of uveal melanoma
•Eastern Cooperative Oncology Group performance status ≥ 2
•Ongoing effects from previous investigational drug studies or concomitant participation in other investigational drug studies
•Prior use of MS-275 or any other HDAC inhibitor
•History of allergic reactions attributed to compounds of similar chemical or biologic composition to MS-275
•Anticancer therapy
•Active gastrointestinal conditions that might predispose for poor drug absorption
•Major surgery within 4 weeks prior to enrollment
•Hypophosphatemia < 2.5 mg/dL at screening, if not corrected in the screening period
•Medical, psychiatric or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study

研究组 & 干预措施

Histone Deacetylase Inhibitor, 3 mg

Experimental

Subjects received 3 mg MS-275 orally biweekly (Days 1 and 15 of a 4 week cycle) or until disease progression or unacceptable toxicity

干预措施: Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894) (Drug)

Histone Deacetylase Inhibitor, 7 mg

Experimental

Subjects received 7 mg MS-275 orally weekly (Days 1, 8, and 15 of a 4 week cycle) until disease progression or unacceptable toxicity

干预措施: Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894) (Drug)

结局指标

主要结局

Overall tumor response rate (the proportion of subjects with the best tumor response of PR or CR within the first 6 cycles of treatment)

时间窗: Baseline, 8, 16, 24, 32 weeks (cycle 6)

次要结局

Time to death(Baseline, every 8 weeks until death)
Tumor response rate at each tumor assessment time point (CR/PR/SD/PD/not assessable)(At baseline and repeated every 2 cycles until tumor progression between Day 22 of even numbered cycles and Day 1 of subsequent odd numbered cycle and also at EOT and F-up visiit (90 days after the EOT and every 3 months until disease progression))
Survival(At 6 months)
Number of participants with adverse events(Approximately 8-64 weeks)
Time to tumor progression(Baseline, every 8 weeks until progression)

研究者

发起方

Bayer

申办方类型

Industry

责任方

Sponsor

相似试验

进行中（未招募）

不适用

Phase II study of MS-275, a histone deacetylase inhibitor, comparing 2 dosage schedules in patients with metastatic melanoma - MS-275 proof of concept in melanoma

EUCTR2004-002395-41-DESchering AG100

已完成

2 期

NCT00462605National Cancer Institute (NCI)24

已完成

1 期

NCT00098891National Cancer Institute (NCI)24

已完成

1 期

MS-275 in Treating Patients With Advanced Solid Tumors or LymphomaCancer

NCT00020579National Institutes of Health Clinical Center (CC)75

已完成

1 期

MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemiade Novo Myelodysplastic SyndromeRecurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaSecondary Myelodysplastic SyndromeLeukemiaAcute Myeloid LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia

NCT00101179National Cancer Institute (NCI)63